Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAFCA caffeine trial in early-to-moderate Alzheimer's disease
2024-514099-41-00Phase 3Authorised
- Sponsor
- CHU de Lille
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Caffeine with Placebo (2 arms). Primary endpoint: Change in total NTB score at 30 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
caffeine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-514099-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514099-41-00.